Summary of Phase III Clinical Trials for Intensification of Upfront Therapy for Treatment of mHSPC
| Trial | Drug | Hazard ratio (mOS) |
|---|---|---|
| CHAARTED | Docetaxel | 0.61 (P < 0.001) |
| STAMPEDE | Docetaxel | 0.78 (P = 0.006) |
| LATITUDE | Abiraterone | 0.62 (P < 0.001) |
| STAMPEDE arm G | Abiraterone | 0.63 (P < 0.001) |
| ENZAMET | Enzalutamide | 0.67 (P = 0.002) |
| ARCHES | Enzalutamide | 0.66 (P < 0.001) |
| TITAN | Apalutamide | 0.65 (P < 0.001) |